Sign in

    Caleb Stubbs • William Blair & Company

    Caleb Stubbs, Ph.D., is a Biotechnology Equity Research Associate at William Blair & Company in Chicago, specializing in equity research for biotechnology and life sciences firms. He has covered companies advancing CAR-T cell therapies and hematological malignancy treatments, including private innovators like AvenCell, and has published detailed reports analyzing efficacy and long-term trends in sector performance. Since joining William Blair, Dr. Stubbs has brought scientific rigor from his prior experience as a Life Sciences Analyst and leverages his academic background and research credentials to support investment decisions. He holds an active FINRA registration with a clean regulatory record and is licensed in Illinois.

    Caleb Stubbs's questions to Allogene Therapeutics Inc (ALLO) leadership

    Caleb Stubbs's questions to Allogene Therapeutics Inc (ALLO) leadership • Q1 2025

    Question

    Representing Sami Corwin, Caleb Stubbs asked if the site-related challenges seen in ALPHA3 are expected at ex-U.S. sites and if there are plans to activate ex-U.S. sites for the ALLO-329 RESOLUTION study.

    Answer

    EVP of R&D and CMO Dr. Zachary Roberts anticipates a smoother activation for ALPHA3 ex-U.S. due to lessons learned and less fragmented care pathways abroad. For ALLO-329, he stated the near-term focus is on U.S. sites, but the company remains open to future international expansion.

    Ask Fintool Equity Research AI